or
forgot password

Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.


N/A
18 Years
80 Years
Not Enrolling
Both
Hemoptysis

Thank you

Trial Information

Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.


This is a prospective observational study looking at some coagulation factors in individuals
with lung cancer. We are looking at BAL and plasma. We would like to see if there is a
difference in the levels and if this is the reason behind the higher incidence of hemoptysis
in patients with lung cancer.


Inclusion Criteria:



- Any patient scheduled to undergo bronchoscopy

Exclusion Criteria:

- Patients with evidence of coagulopathy either iatrogenic or the result of disease
process - coagulopathy defined as elevated prothrombin time, activated partial
thromboplastin time or platelet count less than 100,000

- Patients not scheduled to undergo bronchoalveolar lavage (BAL)

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Jijo John, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Oklahoma

Authority:

United States: Institutional Review Board

Study ID:

14455

NCT ID:

NCT00929565

Start Date:

June 2009

Completion Date:

October 2011

Related Keywords:

  • Hemoptysis
  • hemoptysis
  • Hemoptysis

Name

Location
VA Medical Center Oklahoma City, Oklahoma  73104